G-dase® E is a unique, RNA-guided, nuclease-based technology for programmable cell depletion.

G-dase® E belongs to a new family of Crispr nucleases with a unique mode of action. In addition, the native G-dase E sequence has been optimized by the Akribion team to achieve strong potency and specificity in human cells

The nuclease has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between guide RNA and an intracellular RNA sequence. This specific activation event ensures that only the targeted cells are affected, leaving healthy cells unharmed.

The flexibility and broad potential of Akribion’s G-dase® E technology makes it a promising platform for various therapeutic areas, as by simply changing the guide RNA, the technology can be quickly adapted to target different cells, making it much faster to develop new treatments compared to traditional methods.

Our initial target is developing a new approach to treat HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC). We are also exploring applications in additional oncology indications, as well as in autoimmune diseases, fibrosis, infectious diseases, and more.